REVIEW 3 cited by
PepTune: De Novo Generation of Therapeutic Peptides with Multi-Objective-Guided Discrete Diffusion
Not yet reviewed by Pith; the record is open.
This paper has not been read by Pith yet. Machine review is queued; the pith claim, tier, and objections will appear here once it completes.
SPECIMEN: schema-true, not a live event
T0 review · schema-true
One-sentence machine reading of the paper's core claim.
pith:XXXXXXXX · record.json · timestamp
read the original abstract
We present PepTune, a multi-objective discrete diffusion model for simultaneous generation and optimization of therapeutic peptide SMILES. Built on the Masked Discrete Language Model (MDLM) framework, PepTune ensures valid peptide structures with a novel bond-dependent masking schedule and invalid loss function. To guide the diffusion process, we introduce Monte Carlo Tree Guidance (MCTG), an inference-time multi-objective guidance algorithm that balances exploration and exploitation to iteratively refine Pareto-optimal sequences. MCTG integrates classifier-based rewards with search-tree expansion, overcoming gradient estimation challenges and data sparsity. Using PepTune, we generate diverse, chemically-modified peptides simultaneously optimized for multiple therapeutic properties, including target binding affinity, membrane permeability, solubility, hemolysis, and non-fouling for various disease-relevant targets. In total, our results demonstrate that MCTG for masked discrete diffusion is a powerful and modular approach for multi-objective sequence design in discrete state spaces.
Forward citations
Cited by 3 Pith papers
-
Adaptive Order Policies for Masked Diffusion
A policy network learns to choose unmasking order in masked diffusion by reweighting the loss, outperforming random and heuristic baselines on ordering-sensitive tasks.
-
On the Design Space of Discrete Diffusion Online Adaptation for Molecular Optimization
Online fine-tuning of discrete diffusion models with complementary acquisition, CVaR shaping, density-entropy debiasing, replay, and validity control finds better molecules under fixed oracle budgets than offline fine...
-
Beyond SMILES: Evaluating Agentic Systems for Drug Discovery
Drug-discovery AI agents are built for small-molecule, big-pharma settings and lack peptide, in vivo, training-loop, small-lab, and multi-objective capabilities, even though LLMs themselves can reason about peptides.
Discussion (0). Sign in to comment.